摘要
背景:新的异二聚体双结合位点乙酰胆碱酯酶抑制剂的设计是开发具有扩大药理作用的新型抗胆碱酯酶药物的主要目标。多目标化合物通常是通过混合分子与已知的两个或多个药理学分子结合来设计的,以使其与选定的分子靶点发生相互作用。方法:检测所有化合物对人AChE/BChE的抑制作用。用Ellman法测定抑制动力学和IC 50值。为了预测新化合物的被动血脑透过率,对平行人工膜渗透法进行了改进。为了预测与Hache/hBChE结合的新杂种的结合模式,进行了对接研究。结果:本研究介绍了一系列他克林-香豆素和他克林-喹啉类化合物的设计、合成和评价,发现它们对CHs有潜在的抑制作用,对血脑屏障有潜在的抑制作用。结论:他克林-喹啉杂合7a对hBChE活性最高(IC 50=0.97μ),对Hache活性最高(IC 50=0.32μ)。动力学和分子模型研究表明,7d为混合型AChE抑制剂(Ki=1.69μ),7a为混合型BChE抑制剂(Ki=1.09mol)。此外,杂交5d和7c可以穿透CNS。
关键词: 阿尔茨海默病,香豆素,乙酰胆碱酯酶抑制剂,合成,胆碱酯酶,对接。
Current Alzheimer Research
Title:Tacrine-coumarin and Tacrine-7-chloroquinoline Hybrids with Thiourea Linkers: Cholinesterase Inhibition Properties, Kinetic Study, Molecular Docking and Permeability Assay for Blood-brain Barrier
Volume: 15 Issue: 12
关键词: 阿尔茨海默病,香豆素,乙酰胆碱酯酶抑制剂,合成,胆碱酯酶,对接。
摘要: Background: The design of new heterodimeric dual binding site acetylcholinesterase inhibitors constitutes the main goal-directed to the development of new anticholinesterase agents with the expanded pharmacological profile. Multi-target compounds are usually designed by combining in a hybrid molecule with two or more pharmacophoric moieties that are known to enable interaction with the selected molecular targets.
Methods: All compounds were tested for their inhibitory activity on human AChE/BChE. The Ellman´s method was used to determine inhibition kinetics and IC50 values. In order to predict passive bloodbrain penetration of novel compounds, modification of the parallel artificial membrane permeation assay has been used. Docking studies were performed in order to predict the binding modes of new hybrids with hAChE/ hBChE respectively.
Results: In this study, we described the design, synthesis, and evaluation of series tacrine-coumarin and tacrine-quinoline compounds which were found to show potential inhibition of ChEs and penetration of the blood-brain barrier.
Conclusion: Tacrine-quinoline hybrids 7a exhibited the highest activity towards hBChE (IC50 = 0.97 µmol) and 7d towards hAChE (IC50 = 0.32 µmol). Kinetic and molecular modelling studies revealed that 7d was a mixed-type AChE inhibitor (Ki = 1.69 µmol) and 7a was a mixed-type BChE inhibitor (Ki = 1.09 µmol). Moreover, hybrid 5d and 7c could penetrate the CNS.
Export Options
About this article
Cite this article as:
Tacrine-coumarin and Tacrine-7-chloroquinoline Hybrids with Thiourea Linkers: Cholinesterase Inhibition Properties, Kinetic Study, Molecular Docking and Permeability Assay for Blood-brain Barrier, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180711110750
DOI https://dx.doi.org/10.2174/1567205015666180711110750 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Role of Stromal-Derived Factor-1 in Mesenchymal Stem Cell Paracrinemediated Tissue Repair
Current Stem Cell Research & Therapy High Dose Immunoglobulin (IVIG) May Reduce the Incidence of Langerhans Cell Histiocytosis (LCH)-Associated Central Nervous System Involvement
CNS & Neurological Disorders - Drug Targets Pharmacotherapy for Premature Ejaculation
Current Drug Therapy “The Tools of the Trade” – An Overview of the Pharmacology of the Endocannabinoid System
Current Pharmaceutical Design Candidate Gene Analysis of the Price Foundation Anorexia Nervosa Affected Relative Pair Dataset
Current Drug Targets - CNS & Neurological Disorders Personalized Medicine in Psoriasis: Concept and Applications
Current Vascular Pharmacology Author Index To Volume 5
CNS & Neurological Disorders - Drug Targets The Challenges of Chemical Stability Testing of Herbal Extracts in Finished Products Using State-of-the-Art Analytical Methodologies
Current Pharmaceutical Analysis Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets Translational Challenge Models in Support of Efficacy Studies: Effect of Cerebral Hypoxia on Cognitive Performances in Rodents
CNS & Neurological Disorders - Drug Targets Targetability of Human Disease Genes
Current Drug Discovery Technologies Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design Enzymatic Targets in Trypanosoma brucei
Current Protein & Peptide Science Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: From Vascular Spasm to Cortical Spreading Depolarizations
Current Neurovascular Research Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Calcium Intake Requirements Along the Life Cycle and Associated Factors
Current Nutrition & Food Science The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry